GT Biopharma (NASDAQ:GTBP) Issues Earnings Results

GT Biopharma (NASDAQ:GTBP) announced its earnings results on Friday. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03), FiscalAI reports.

GT Biopharma Trading Down 10.3%

Shares of NASDAQ:GTBP traded down $0.05 during midday trading on Friday, reaching $0.39. 3,999,203 shares of the company were exchanged, compared to its average volume of 1,197,280. The business’s fifty day moving average is $0.40 and its two-hundred day moving average is $0.57. GT Biopharma has a one year low of $0.26 and a one year high of $3.85. The stock has a market cap of $14.03 million, a PE ratio of -0.06 and a beta of 0.64.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GT Biopharma in a report on Friday, April 10th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

About GT Biopharma

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).